Rosenoff, S.H., Gabrail, N.Y., Conklin, R., Hohneker, J.A., Berg, W.J., Ghulam, W., … Anthony, L. (2006). A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: Results of the STOP trial. Journal of Supportive Oncology, 4(6), 289–294.
To compare the efficacy of two dose levels of octreotide long-acting release (LAR) in preventing chemotherapy-induced diarrhea (CID) in patients with active or prior CID
A sample of 124 evaluable patients were assigned randomly to either the 30-mg or 40-mg octreotide dose group. The first dose of ocreotide was given intramuscularly 7–14 days prior to day 1 of the patient's next chemotherapy cycle. The second dose coincided with the chemotherapy cycle. Subsequent cycles were given every 28 days up to a total of 6 doses on a schedule independent of the chemotherapy cycles. Prior to initiation of octreotide LAR, patients were given a 100-mcg test dose of octreotide subcutaneously to determine potential intolerance.
This was an open label, randomized, multicenter study with a parallel-group design.
No specific recommendations regarding the superiority of 30 mg or 40 mg octreotide in the management of CID can be made based on this study.